PBYI - Earnings call transcript Q2 2020 | Puma Biotechnology, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. My name is Jesse, and I will be your conference call operator today. At this time, all participants are in a listen-only mode. After the speakers' formal remarks, there will be a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded. to Director conference Biotechnology. of like Mariann over now Senior Ohanesian, IR would turn call the to I for Puma

may conference. begin You your

Mariann Ohanesian

conference financial Jesse. to quarter you, Good and to Thank afternoon, of XXXX. discuss for results Puma's our the second welcome call

results. Chairman the XXXX on that for Chief and The news website via forward-looking pumabiotechnology.com. of risks securities Financial conference statements statements to will and include Officer. quarter Today's and the and call are laws. our that days. Jeff webcast release, Jeff Company's Chief plans, the Sections will That available next me Officer; at Officer, the on and archived accessible financial news Auerbach, of XX subject factors of federal After periodic call for webcast results Executive the expectations, Puma; and refer filed second uncertainties, Commercial time today, to purposes Puma those due the include to detailing in differ prospects a expressed today disclosed a Securities are a Investor and the actual release number replay than Exchange about website and call which slides Such factors, for Joining Board homepage Puma future market statements current forward-looking presentation Alan Commission from these the of in may reports and and to, of are statements Chief by slides risk time. constitute and our be President this will of Nougues, issued close Maximo Ludwig,

forward-looking to conference no to this as the statements, reflect of law. or X, The call, place after date by revise any not of circumstances events statements undertakes reliance undue are as forward-looking only required live date on of to update Company call, which the August conference XXXX. or this except obligation speak You these cautioned

substitute measures a investors financial metrics to GAAP certain may to refer released turn but a our our Alan. for these we Please to measures. call also call, financial results. now will over that today's to figures. XXXX of as involve news We quarter GAAP to supplement to non-GAAP not GAAP our to I useful for During the non-GAAP be second believe adjustments non-GAAP our reconciliation may refer

Alan Auerbach

the XXXX, in for reported representing from sub-licensees. Thank reported sales you, $XX.X you first a quarter from second the Mariann. well second in QX royalty revenue million. call XXXX, U.S. the quarter Net Today, XXXX. in as sales, of increase quarter and a XXXX and $XX.X And net total million of thank Puma our all NERLYNX of reported as today. joining million Revenue $XX.X the license from our decrease sales of were slight includes $XX.X NERLYNX fees of Total the in net for million

quarter one As pharmacies, we also in of fourth was quarter an four weeks call inventory. estimate XXXX, approximately on of during approximately there we specialty reported the which fourth excess increase there our in on fourth reported an earnings our purchased the by quarter inventory week distribution we call, our And network. was of inventory earnings was

demand. drawn we to had the inventory Our pharmacies that of their quarter down some excess reported first specialty meet call,

our the first However, distribution maintained end at quarter. network of of still the four weeks approximately inventory

inventory believe million. pharmacies revenue we million by demand, continue to second to their which may down second the $X During quarter, specialty existing approximately to have quarter negatively impacted meet draw $X from we saw

million, which the license in with XXXX. quarter in prior the during of $XX.X due the approximately quarter, to level XXXX three inventory a network approval the fourth at in to distribution inventory second the of will with the of had included will and I which weeks one-time is more will mainland $X.X was NERLYNX second of end quarter during XXXX, Also of provide quarter commercial million. components the seen buy Maximo China, XXXX. Our on royalty review of the payment our fees increased of regulatory with Jeff and NERLYNX activities. during the more some a revenue statements details follow the highlights of for the Nougues Ludwig financial quarter, quarter of begin of then line of in the highlights key first

referred incidence the investors results to an while techniques of anti-diarrheal of may a publication this can are variety use that We of demonstrated several neratinib of control neratinib strategies. adjuvants trial, to drugs be which improved early help of breast with anti-diarrheal drug increase the that to ongoing prophylactic are the has further tolerability trial the and the tolerability to of the improve these the aware, of the believe tolerability of incidence additional anticipate reduced, we were to will and increase Annals reduce the three investigating as awareness journal, published be the Oncology, medical techniques, Puma As using of will presented results in drug. of can trial these control the the from extended XXXX, HERX-positive diarrhea XXXX. be results diarrhea use of awareness trial or further the grade We in and using in prophylactic techniques. improve of including cancer, significantly from the fourth dose quarter of help the neratinib of These May related escalation, Interim drug. online the

such in in cohort neratinib plus then patients. than mutation aware, the an enrollments. first respond, patients expanded arm one patients if or four enroll neratinib to will given up patients fulvestrant less plus investors fulvestrant the a further HERX-negative responds, has to stage early the ER-positive receive plus SUMMIT Puma in The alone, arm be arm the randomized patients of trastuzumab. As or as mutated respond, who also the enrollment. expanded, and of HERX enrolled. ongoing trastuzumab, study in close HERX that XXXX, stage, will fulvestrant in amended Each of cancer was SUMMIT closed to trial. during will be referred combination arm either If will than one, the patients cancers, trial that basket are patients breast trial modified the patient have be be expanded be will will arms more four arm to no a be that will XX and If further to further If more responds, seven

during XXXX end in slightly pandemic. XXXX, declined month we quarter again the did the month due monthly the to was enrollment of during enrollment lower month As the believe of decline reported however, this trial did XXXX, higher on trial the not the to then our June, in in be that than slightly into April, call, we during of a improve of towards improve in of level slightly due impacted QX saw QX first began and of March the this the we in in of decline Enrollment of to July. SUMMIT May, to further that then was appear to but range Enrollment the impact the pandemic. enrollment that is COVID-XX and COVID-XX cohort in earnings

enrollment continue by in COVID-XX trial the believe We impacted that to is being the pandemic.

the breast receive will the for of anticipate initial in QX two-stage cohorts results initial cancer continue to that XXXX. We HR-positive from Simon the we

from receive the one schedule breast an the we approval. two-stage this any cohorts, COVID-XX, that also Once and we in later additional uncertainty accelerated associated for recognize COVID-XX, with the should of However, initial impacted recognize FDA with could we the be occur wave this by discuss continue potential year. the to pre-NDA Simon the potential results plan meeting HR-positive a to to

of as Phase the July the with line were data of of HERX-positive now were NALA referred trial, Oncology recently cancer for metastatic Journal we this Jeff Clinical from of of also And her mutant SUMMIT July the of breast third addition, that of of for I announced the published the the this Ludwig, well. commercial to as year. metastatic in our the turn cohort over II the neratinib of in the In will Journal II call our during online in Commercial trial Oncology review to Gynecologic Chief cancer, Officer, Phase finally, year results performance to Puma's a in cervical trial treatment quarter. published the

Jeff Ludwig

It appreciate be great is organization. honored Really leading to be it. to Puma's here, and I'm commercial Alan. Thanks,

of do to have to much are accomplished patients We support what there know we so their battling more proud is far, breast families but and clearly cancer.

Before reminder forward-looking I move a that review, just I into commercial making the be will statements.

pandemic. COVID-XX of Puma's impacted the quarter access second by the During was commercial negatively XXXX,

call, reported As starts patient quarter from first see impact in an on QX. earnings we did COVID-XX we new on our not

However, impact mid-QX. we in see did an

stay-at-home and to We latter in was to we did, our believe essentially May, that been which of patients As number new those the more states did back part up related up we see This was in month, the trend June, signing were in in March. reported, start pharmacy the orders signing to U.S. to parts beginning pandemic place decline we in open due the specialty a previously which the of compared up. specifically, flat channel various may recover have and to in in the April however, believe through of COVID-XX quarantines

other May cancer breast of similar early We June. reporting who to are companies in drugs HERX-positive stage have aware dynamics and treat

cancer may on believe broader had breast So stage impact this we a impact have early COVID-XX that the market.

the as provide patients. our specialty represented have We sales similar the As pharmacy but quarter, net quarter. channel XX% X in NERLYNX the since of reported very specialty Maximo to sold we distribution is results, channel, the provide will now channel and you approximately two I U.S. approval. may specialty to second distributor of the call, dispensing full in the U.S. that with Slide in XX% or first we refer will these sold quarterly NERLYNX current in you our channels This bottles quarter. FDA the recall, sales bottles In shows channel. review in-office the Later the results. total to financial

sales we over since sold X,XXX of NERLYNX X sold As We were reported in in which from about of noted, XXXX, launch. of product reported bottles XXXX. our XXXX X.X% net a sales X,XXX. second the increase bottles Slide NERLYNX million is the QX $XX.X slight $XX.X QX of of a of Alan quarter bottle is of U.S. by million in This decrease our QX the shows quarter XXXX.

mentioned, Alan like distributor in correlated inventory. as with decline. we not see an sales one-week believe do we clearly, But reduction approximate directly Now, is this bottle to

new environment, and Our compared and patient impact. despite see demand to gross flow decreased commercial to hard very to worked adapt pleased are access flat that has stayed have reported COVID teams customer to we this QX,

new breast highlighted it as escalation interim by believe dose milestone, in PRN for showed As brought NERLYNX three the the the of HERX-positive that reduction of published a patients of line QX in option patient greater metastatic management than results third online setting. reducing NERLYNX business in grade metastatic were in our metastatic for coupled control loperamide, our with cancer. and that of In setting, larger an overall be approximate management to it an extended of QX, important, data XX% control diarrhea starts in XX% forth our discontinuation. Oncology roughly diarrhea three We majority This of a received Utilizing treatment grade significantly and continue Alan the mentioned adjuvant tolerability treatment proactive important an during discontinuations. XX% and clearly call, X% new to disease. as of in trial overall approval reduction shows Annals The May. strategy our improve extended vast earnings the battling was starts patient diarrhea additional setting. the very the in can were is

of see reduced XX% approximately dose QX, you X, patient increase in which As a new were can at over starts QX. is initiated a in slight Slide

the and communication NERLYNX with tolerability the an cancer. We their trend the should of reducing With in believe continue. we recent expect that ultimately, patients would increase publication, discontinuations help additional battle QX, average to length this improving plan in coupled and, therapy breast of with

the with regional NERLYNX world and have with pharmaceutical within the that of strategic respective available expertise partnerships, on we formed rest Moving have partnerships world. of to commercial goal their companies across making to patients regulatory geographies, the

NERLYNX and slide. trend countries has continued Taiwan. reimbursement Israel outside in in Medison approved Zealand in national Argentina year. yesterday, During in in Therapeutics launched of received approval and in in this on recently, in received Brunei was and regulatory both XXXX, this just in Pint and in the earlier Pharma Specialised April, United And approval this CANbridge received finally, year, QX approval NERLYNX received New April. late XXXX, regulatory June, several approval as States, seen Malaysia July. Most this this in in on And Chile

During Fabre, the additional the America, remainder quarter, approval Austria. Middle the in they including in in look Kingdom, be regulatory NERLYNX and potential Asia, Southeast Pierre In partner, in East. of Europe, NERLYNX to in for XXXX countries, launched and received forward to in Asia, Latin Recently, the we fourth and approved Sweden beyond, our United the launched Germany, and Switzerland. NERLYNX

have Although Europe we NERLYNX XXXX. initial that review remainder it progress is their been the our in to of throughout on early, success, investors updating the Maximo will and financial will over anticipate launch results. with a now the additional call European of forward countries Fabre several Pierre very still in pleased we turn We to our I future. for look in

Maximo Nougues

XXXX note QX that our summary and year-over-year results company XXXX, a of will comparisons. commercial Thanks, our the better financial indications which quarter comparisons Please believe of we second QX make Jeff. and with I a to XXXX. are I as of progress for will begin brief

For XX-Q, refer more you statement. includes consolidated to will be today, that which I information, recommend and financial our our filed

the $X.X XXXX, $X.XX million net For or reported second of GAAP diluted quarter income share. per based of on we

net XXXX XXXX is million compensation, which $XX revenue $XX.X XXXX. On impact from of million income QX $XX.X adjusted to were remove versus non-GAAP diluted $X.XX share QX. and million Our million, the quarter for or was losses in the for basis, of sales net Gross million NERLYNX stock-based respectively. GAAP XXXX and of per reported QX in $XX we second a QX $XX

revenue XXXX. global $XX.X increase partners. net slight from million, net $XX.X mentioned, recognized of QX the million $XX.X million revenue, from in a was $X.X and revenue in sales royalty quarter of NERLYNX XXXX, from sales license In Alan in we first our As million

was net approximately Our driven Cost in of the was payments $X.X copay expenses, net XX.X%, to the quarter of decrease was by lower to $X.X and driven which for million, gap QX. XX.X% adjustment by The licensor milestone gross amortization of mostly gross in adjustment second million. a of QX sales the coverage decrease included the seasonality. to neratinib from

forward, Going of amortization payment licensor to the per $X we for of will sales. quarter to milestone about million continue recognize cost the

will million NERLYNX of $XXX sales be from full $XXX anticipates year Puma XXXX, is the that million. $XXX prior For $XXX estimate deduction our net million. in to range This to of million

XXXX million, We between royalties, a fees of we with million. XX%. range potential our will our in the of XX% from to net the that licensee this in the full deal gross receiving for to anticipate $X amount to fees. and negatively adjustment also We and in partners anticipate our is around continue royalties and COVID-XX, of there may XXXX, to of great to and world be continue $XX.X impact Furthermore, sales, impact year the $X recognize uncertainty the regards license million

approximately burn million and million ended to $XX.X quarter net the $XX.X in will expenses second QX compared Puma QX earn cash $X.X were million XXXX second be million in second of to million R&D to QX second XXXX, XX.X% the for $XX XXXX, of QX Additionally, Research expenses quarter and in respectively. compared XXXX with $X.X expenses $XX.X of XXXX, million $XX.X for including $XX.X $X.X and non-cash QX charges $XX.X million in $X.X second respectively. compared million $XXX.X compared to the million QX and cash QX, XXXX of stock-based charges million of QX million, QX QX compared approximately XXXX, SG&A expenses, respectively. gross securities. We reported of million of respectively. $XX.X our million XXXX. In QX QX marketable cash, $X.X to anticipate million cash were for quarter, million XXXX of million. compensation, in QX and SG&A the million net of and for XXXX, and NERLYNX non-cash to stock-based and to the revenue for We equivalents, million $X.X the included cash quarter to earn XXXX and that for were XXXX, $X.X range quarter $X expectations in XXXX the in in $XX development are XX.X%. and for for XXXX XXXX, compensation

accounts receivables at million. XX was $XX June balance Our

our Our neratinib approximately that and days. the outsandings network while we our We through clinical XX commercialization accounts receivable days, resources of XXXX terms to of are financial our three ranging as weeks between maintains focus day NERLYNX. trials deploy XX the June of XX, days and estimate XX advancement distribution ongoing about of Overall, inventory. sales continue on to

Alan Auerbach

Maximo. Thanks,

We continue Committee to on and with and improve n of cooperation continue growth Board in revenue the remain senior XXXX in NERLYNX beyond. Puma's Commercial sales to sales need recognize NERLYNX Directors, growth. the management, that of we focused to

hires have pandemic. environment that team, we a made to We toward, in adapting virtual and our number need the we of to are pivot commercial to commercial new due COVID-XX also the

for are changes and continues need We we achieve updating make journey, their that this committed and and to There contribution on look a infrastructure continue Puma This passionate and members during finding to more at in cancer. presentation. NERLYNX effective to team growth, about will today's strive to positive helping concludes We investors the we women significant goal. hopeful unmet to that breast these forward these commercial and to will a patients sales new our battling are remain ways future.

operator will turn now the back Operator? for We QA. floor to the

Operator

you. Thank

question-and-answer We Thank will session. [Operator you. now the Instructions] begin

with Our first Citi. question. comes the from proceed Yigal question Please with line your Nochomovitz of

Samantha Semenkow

Yigal. for our very Thanks for much taking on Samantha is this Hi, questions.

far, the off-label [indiscernible]? solid so other just of First, contribution as metastatic cancers, do see indication? develop seen have you've you any I given on work -- And benefit evolving HERX-driven picture want of revenues NERLYNX you use you overall to the how to with seen this start to

Alan Auerbach

question. the for you Thank Samantha. Hi,

in XX% is somewhere to I X% our presentation setting. metastatic his Jeff between of said So in that believe the usage

I that's what So we've think remained see. to continued

as have they it's metastatic HERX-positive using script behind mets, in don't, from her I or whether when HERX-mutated, Now, anecdotally, not that we and breast definitely say in hear mets. of in physicians exactly certainly NERLYNX for or or that know commercially a they're metastatic has that come numbers they breakdown don't cancer HERX-positive two we are mutated unfortunately, it mets. have or brain brain have I can brain breast don't that. a metastatic, they cancer, using the they're any

Samantha Semenkow

And That's guidance, then Got adjuvant helpful. both and that that on it. on confirm correct? is metastatic. for the that setting wanted yesterday's to guidance, I just the the Is

Alan Auerbach

is that correct. Yes,

Samantha Semenkow

so Okay, much Thanks great. our for taking questions.

Operator

Thank you.

next from comes Kennen RBC. Please line Our of with with Mackey question question. your proceed

Unidentified Analyst

Hi, for Kennen. this questions. on our is Kim for Thanks [ph] taking

proteins, is research of identifying publication COVID-XX; neratinib viral of an question structure the protease research recently, dive followed first four looking the resembled just functional using So about computational The paper a kind side, interesting the different -- that main main classes chemical which neratinib's earlier looked inhibitor, potent can like class. as an in moiety into MX nature, the approaches. kind

this your awareness biochemical sound your research Thank come and acids, and And to kind animal interest will of do studies, you. into maybe too? that does So trigger clinical trials?

Alan Auerbach

our Yes, the COVID-XX, neratinib researchers to COVID-XX. in many who coming publication active say, to up we research, the don't in this publishing work but that you interest investors, in, have in that to types it been work had conclusions. hi. and have on way group. I or more public some way, will to And done have for from looking is about are it by under have some into. something we is we either suffice communicate it yes, get we it information. Yes, that of in who we be Once it, to, that something we with of much had neratinib have Russian investigators too getting research plan data have with some want we Thank some say I similar think external belts, But aware question. doing on

Unidentified Analyst

follow-up one cohort the HERX-mutant on have cancer update. we Then cervical you. Thank

And data we for safety our the cancer enrolled next approximately know SGO required cancer timing so the advocacy the included the how cohort to far? how patients by more patients' analysis. for discussion? all into the data compared on provide data may and patient the more the five data -- So, there more Can cervical one Thank questions. many are you And been included that's cervical regulatory guidance update, many data, you. and FDA have analysis, with for were patients' size and

Alan Auerbach

Thank of don't you I on cervical the we cancer. have know on exact the I data that. HERX-mutated presenting more that. me. on know for timing do of question not apologize. I update do plan the the front on I in that

need I'll that. to you get back So on to

for patients would apologize to it I me. that be is, about front cancer to go do not question, with And which population. the is FDA again, cancer, So them? having many and X% HERX-mutated need how recall, I SNDA. of in your cervical as of we This an To the discuss cervical

not Keytruda there So of XX,XXX smaller. in know think patients don't instance, I a like it's was aware or for PD-LX obviously something. And high, number. I much and It's huge the end got -- I'm approved

not we're here. patients to I'm need imagining hundreds of So going

Let would of the a and you little update label. an our be me expanding with back that where get for to on timing is what more

Unidentified Analyst

really Thank helpful. you. That's

Operator

Thank you.

JPMorgan. proceed question. with from Our Cory Please comes Kasimov your next question with

Unidentified Analyst

my at for to comfortable NERLYNX XX% taking NERLYNX over pricing. for currently Matthew expect months? just This where or I'm is Cory. foreign on Are pace priced, each increases increases on the Thanks of Hey, your last is occurred the guys. should XX we be question. that thoughts you has similar the wondering to

Alan Auerbach

Jeff, if that? you'd like to handle

Jeff Ludwig

in But what Good tell want ensuring it is you Matthew. the way I We we very we're to think very I I committed pricing a question. appreciate it. proactively say to very, of that. are proposition I value about would going to not any wouldn't you comment on will strategies. mean, future Hi, do marketplace. first potential is strong Sure. this all,

look continue strong physician marketplace. at our obviously, We also and want very patient we is of to to the And there discussions, as that part ensure competitive access.

decisions. past, made this pricing comment at future decisions we in but wouldn't any point on potential the we've some So

Unidentified Analyst

Great. my Thanks for taking question.

Operator

you. Thank

Our Please proceed next your Geoff from line question of Bank with comes of America. with Meacham the question.

Unidentified Analyst

for is no for it as statistical Hey taking to specifically difference guys, question. the OS ExteNET years relates in insert added to language follow-up. of the Thanks new recently, our after Scott there Geoff. trial, the believe in I to package eight this NERLYNX of was regards on

So lower doses dose the the they wondering on milligrams? how it's and are And on results difference these moving them typically benefit, DFS then guys impact patients? you aren't small do you lower forward? just this the how reach potentially these And whether the impacting dose that placebo what are more for will to that equivalent average lower starting the the the think patients until this Thanks. the you duration in is XXX making patients or are know the sales dose, starting on and patient given confident OS,

Alan Auerbach

and patients, your the receptor answer ExteNET of it and population, a trial receptor ITT in hormone wide rolled to in negative know, was patients. range first the the you positive So question, as Scott, hormone

As to a It's you group can't this use drug But specifically have the know, positive those all impact clinically risk. think were the or be we the at plan and the understand in that from cohorts, where impact it comment the HR-positive our at I wait HR-positive on Breast until positive and in year. high-risk patients, what to We hear group can please? those And meeting Cancer see Antonio from is. Can it used San second patients the clearly, a on to are your that. But the HR-positive if in is logic. who ITT population. a it comment tend HR-positive on can't could not presenting Obviously, commercially, and higher data does we sales. question, data on you yes, subgroups, Obviously, that actual comers. physicians that, use the for to have we we repeat you presented, not think you it we drug in is the they the the typical be of

Unidentified Analyst

sure. Yes,

that Just the dose the they patients know until of what on wondering XXX? that kind if potentially you given dose. it? And dose survival the lower lower on dose the and overall about they're starting having the the patients reach lower are Do GFS, kind on this look as the duration, at typically on tighter the is of benefit, any or in impact you range these

Alan Auerbach

Okay.

first second part I I'll Jeff will So take question of think take and that part,

Jeff Ludwig

at pills the presented, that was the arm, the for at what that pills patients in data we're up you're suggesting then And in the paper, opening about three good least Obviously, data and if second that the about on first does four as to in it's change feel question. NERLYNX. think you a week. on the tolerability the to statements dose data, Scott, start and follow escalation that we paper is I highlighted control it week, week, for dose good full control And the of our we very third significantly the

again, customers that's that many data That's the the are out there. have protocol beginning we So adopt. that to

somewhere that's get do in average study, we to idea milligrams. So to to microgram XXX have ultimately, is the or flow. that the is some but And really around And where patients ultimately, was relatively ExteNET so dose In full variability, dose. up the the you the the near patients future. expect get

when that, dose the Given negative happens see escalated efficacy. we quickly, do on expect to impact relatively a not

asked Now, question broader a about… you

Alan Auerbach

three would be six be milligrams would dosage, would day. the terms the up, pills XXX a pills and the be day pills a Just the to XXX, follow of four XXX, in

answer ways. I question, your impact efficacy? expect it that of to terms we two in In do can

the I were remember that full First off lower it lower lower remember imagine two looked patients about was had we -- efficacy back XX-month and And in they're that way actually And were on XXX lot at much weeks the compared to to again, I two down of dose had the a in was, at plus the look, a tolerability. talking very we to weeks was those in when or dose we somewhere were of subgroup. efficacy. will started all, compromise head, weeks that outlined, the compromised just and dose at efficacy going dose And much, wouldn't do top I impact a where XX% XXX XX the milligrams, I there it's for I in my correctly, also the at Jeff escalation I this dose. that -- they lower ODAC but if a stayed in guess whatever, forward. gone note if the in number course any, or was looked negative ExteNETs don't lower XXXX, then control to is a range it's preparing doses. patients have trial, as those of if therapy. of the to going And getting you're on a first based not that don't dose milligrams, the XXX milligrams, that XXX had of on patient went of that milligrams, remember they in the

Unidentified Analyst

Thanks, helpful. it Got very guys.

Operator

you. Thank

question comes Paul question. with from next Goldman Sachs. Our Choi your with Please proceed

Paul Choi

to can studies as you have next competing conduct sized? seeing or to pre-NDA given you My the half commercial Is maybe And salesforce, in Thank on meeting? you'll interaction just -- if is Jeff. that and with Thank you for regard there? just capabilities. breast now, ahead the Salesforce analyses the the you'll in HERX-mutated metastatic additional just everyone. how you're other us right much. your good go cancer any right I'm just you're my the particularly market you, sort the first pre-NDA virtual very given meeting just is question maybe of then feedback, question dynamics comment afternoon, for into what year, remind your of seeing And regards with agents front to out second

Alan Auerbach

Okay, Jeff, you to the one on take the first want salesforce?

Jeff Ludwig

Paul. for have with now Thanks wish on know right ultimately, adjust environment have to have months of force to. a pandemics none for And we're direct several the and had COVID new to of additional which, Obviously, the I happy question, that, field seen, customers many ball, trying and Yes, likely guess least highlighted, go as I Clearly, before. well, been significantly. others that access unique fortunately, amount adapt through highlighted, to but the you've is as we the here. changed environment, to I I crystal a at us pivot to

to situation pivot think interactions going or pivot interactions with is some or as much can and are very back or regional localities to decision. what we as will customers. about we And remote to this in tried really a this interactions. on, we've still up, open to So live do, local we virtual as regions Paul, live quickly where There

voice we've interactions, video, Given and happened lot, peer-to-peer Zoom, programs, ultimately, increased strong maintain share not phone, that a tried has that to a through etcetera. increased significantly non-face-to-face

about we're so, can. to that, continue feel our we environment, And evolve as we adapting to that and we good ability will to best in all pretty compete but

in fill we right our currently diligent smart and are very not our that and we sized, being as and to opens a teams making whether with and sure want role very also closely are or whether or We future. going fill position head up, counts, to the we're decide evaluate or we're that

the utilization of So we're with as smart time well. this resources being given very

Alan Auerbach

file then be we is And Simon to discuss what that neratinib, year, of be arm do population, was to on one remember the the able second Herceptin, FDA Herceptin, neratinib's other in was And alone. Simon patients, -- us down and regarding October triplet, shut is the the two-stage for works better a triplet, to where the we've way help the one. the correctly, September, us them contribution And had neratinib you arm fulvestrant you you data what breast if fulvestrant, if the on last the is fulvestrant in seven so necessary I trial. seven of it we of the see to fulvestrant, would end an and meeting was asked arm. to the therefore in each modification the other HERX-mutant is HERX-mutated question what at arm which a NDA the is Herceptin Paul, responder one understand that with And two-stage, And first done, don't plus had an do to shown indication. the to the they time to the plus and

If you it responder, you do XX see patients. a expand to

would a other to then we and see So, what arm that's I arms, see in I any for know that the to that in two we response if continue easy triplet further the answer. we we data to imagine pretty need the need to do. think same one to rate don't wait analyses responses

responses If to then reason, need NDA. some you going the follow what others, before we exactly to a going that's have for be we're seeing end can know up to think data that and the But I different situation. wait to we for

Paul Choi

that. Great. for Thank clarifying you

Operator

our for turn to like back conference Mariann concludes This I comments. to over would you. session. question-and-answer this closing Thank

Mariann Ohanesian

Thank Biotechnology. you for Puma interest in your

accessed a replay As evening. call webcast pumabiotechnology.com, a may Have today. a be reminder, later at by the beginning of this good

Operator

concludes Ladies Everyone, you and call. in day. conference participating have gentlemen, for a This our today's thank program. great

disconnect. now may You

Puma Biotechnology (PBYI) 7 Aug 202020 Q2 Earnings call transcript